CATXHealthcare · Medical DevicesThe 16 Wall Street analysts covering Perspective Therapeutics, Inc. hold a median 12-month price target of $13 — +293.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 30 of 100 as at 22 Aug 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Perspective Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Revisions (72): Analysts have, on balance, been raising their forecasts.
Issuance (18): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on CATX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +293.9% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 19 Aug 2026 | BMO Capital | Initiates | Outperform | — |
| 14 Aug 2026 | B of A Securities | Maintains | Neutral | — |
| 11 Aug 2026 | Piper Sandler | Maintains | Overweight | — |
| 5 May 2026 | BTIG | Reiterates | Buy | — |
| 5 May 2026 | Wedbush | Reiterates | Outperform | — |
| 20 Apr 2026 | Wedbush | Reiterates | Outperform | — |
| 23 Mar 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 18 Mar 2026 | B. Riley Securities | Maintains | Buy | — |
| 18 Mar 2026 | UBS | Maintains | Buy | — |
| 18 Mar 2026 | Wedbush | Reiterates | Outperform | — |
| 17 Mar 2026 | BTIG | Reiterates | Buy | — |
| 17 Mar 2026 | RBC Capital | Maintains | Outperform | — |
| 19 Feb 2026 | Piper Sandler | Initiates | Overweight | — |
| 30 Jan 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 30 Jan 2026 | Wedbush | Reiterates | Outperform | — |
| 13 Jan 2026 | BTIG | Reiterates | Buy | — |
| 21 Nov 2025 | UBS | Maintains | Buy | — |
| 18 Nov 2025 | B. Riley Securities | Maintains | Buy | — |
| 13 Oct 2025 | BTIG | Reiterates | Buy | — |
| 10 Oct 2025 | BTIG | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CATX appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 86% of US stocks
Cheaper than 1% of US stocks
Cheaper than 70% of US stocks
Cheaper than 67% of US stocks
Higher than 3% of US stocks
Higher than 1% of US stocks
Higher than 30% of US stocks
Higher than 24% of US stocks
Higher than 18% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Perspective Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
A Zacks Research article examines how Perspective Therapeutics (CATX) and Bristol Myers Squibb (BMY) have performed compared to their sector so far this year, asking whether medical stocks are lagging CATX.
Why it matters — CATX watchers would care because it shows how the company's year-to-date performance compares with its sector and peer Bristol Myers Squibb.
Zacks reports that the medical sector's earnings season is off to a strong start, and it identifies four biotech companies as positioned to potentially beat estimates in their upcoming quarterly results. The excerpt does not name which four companies are highlighted.
Why it matters — CATX watchers may note a positive earnings environment in the biotech sector, though it is unclear from this report whether Perspective Therapeutics is among the four companies mentioned.
Perspective Therapeutics announced it will report its second quarter 2026 financial results and provide a business update on August 10, 2026 after the market closes, with the press release to be posted on the Company's website.
Why it matters — This is a scheduled update that will allow CATX watchers to review the Company's quarterly financial performance and hear management's commentary on its radiopharmaceutical development programs.
Zacks Investment Research reported that Perspective Therapeutics (CATX) formed a hammer chart pattern after losing value, and noted an upward trend in earnings estimate revisions.
Why it matters — CATX watchers would care because the hammer pattern and rising earnings estimate revisions are technical and fundamental signals that the article highlights for the stock.
Perspective Therapeutics announced that the European Commission granted orphan medicinal product designation for [212Pb]VMT-α-NET in gastroenteropancreatic neuroendocrine tumors (GEP-NETs), following a positive opinion from the EMA's Committee for Orphan Medicinal Products.
Why it matters — Orphan designation in the EU can provide regulatory and commercial benefits for a candidate in Perspective's pipeline.
The 16 Wall Street analysts covering Perspective Therapeutics, Inc. have a median 12-month price target of $13, with estimates ranging from $5 to $18. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 16 analysts covering Perspective Therapeutics, Inc., 15 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Perspective Therapeutics, Inc. 30 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 22 Aug 2026, Perspective Therapeutics, Inc. ranks 30 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (72 of 100).
No one can know that. What the data says: the median 12-month target from 16 analysts implies +293.9% from the last close, and Ticker Nerd's factor model ranks Perspective Therapeutics, Inc. 30 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Perspective Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CATX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $5 to $18 over the next 12 months.
Perspective Therapeutics, Inc. returned -7.3% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Perspective Therapeutics Inc. is a biotechnology company focused on the discovery, development, and commercialization of innovative therapeutics and technologies to treat various diseases, primarily within the oncology sector.
The most recent item we track (Zacks Investment Research, 4 Aug 2026): "Are Medical Stocks Lagging Perspective Therapeutics, Inc. (CATX) This Year?". A Zacks Research article examines how Perspective Therapeutics (CATX) and Bristol Myers Squibb (BMY) have performed compared to their sector so far this year, asking whether medical stocks are lagging CATX.
Perspective Therapeutics Inc. is a biotechnology company focused on the discovery, development, and commercialization of innovative therapeutics and technologies to treat various diseases, primarily within the oncology sector. Its primary function is to advance research that can lead to practical cancer treatment solutions, potentially impacting patient care significantly. The company engages in developing novel targeted therapies, often collaborating with leading research institutions and utilizing cutting-edge scientific techniques. Perspective Therapeutics Inc. plays a critical role in the healthcare market by addressing unmet medical needs and contributing to the growing demand for personalized medicine approaches. The work undertaken by the company holds substantial importance for the biotech and pharmaceutical industries as it seeks to improve therapeutic outcomes and enhance medical capabilities in combating cancer and other serious illnesses. The company's initiatives not only underscore the importance of biotechnology in advancing healthcare solutions but also highlight the ongoing evolution within the medical research landscape.
CEO Mr. Johan M. Spoor · 163 employees · United States · https://www.perspectivetherapeutics.com